Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of the key efficacy and safety findings of the recent phase III ENLIGHTEN-2 study, which evaluated weight gain with ALKS 3831 (olanzapine and samidorphan) versus olanzapine in adult subjects with schizophrenia (ClinicalTrials.gov Identifier: NCT02694328).
1. What have been the major efficacy and safety findings of the ENLIGHTEN-2 study to date? (0:08)
2. How do you expect olanzapine/samidorphan to fit into current treatment paradigms? (3:45)
See also the 1st part of this interview: Christoph U Correll – Phase III ENLIGHTEN-2 Study in Schizophrenia (Part 1)
Disclosures: Prof. Correll has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva; he has provided expert testimony for Janssen and Otsuka; he has served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus and Teva; he has received grant support from Janssen and Takeda; and he is also a stock option holder of LB Pharma.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Psychiatric Disorders
Treatment algorithm for managing treatment-resistant depression: Charles Nemeroff, APA 2023
Guidance following the failure of monotherapy when treating depression is limited, as such clinicians usually take a trial and error approach to treatment, a treatment algorithm could help personalise patient care and achieve improved outcomes. It was a pleasure to talk with Dr. Charles Nemeroff (The University of Texas at Austin, Dell Medical School, Austin, […]
Major depression treatment landscape, unmet needs and emerging therapeutics: Charles Nemeroff, APA 2023
Despite being one of the most common serious psychiatric disorders, major depression remains difficult to treat with only 30-50% of patients achieving remission from monotherapy or talk therapy, however many promising new antidepressants are currently under investigation. We were delighted to talk with Dr. Charles Nemeroff (The University of Texas at Austin, Dell Medical School, […]
Barriers when implementing positive psychiatry interventions: Erick Messias, APA 2023
Implementing positive psychiatry approaches can face various barriers across different levels of care. These include resistance to change, limited resources, time constraints, and the dominance of a deficit-focused model. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how to address these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!